{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,19]],"date-time":"2026-11-19T22:34:42Z","timestamp":1795127682335,"version":"4.10.3"},"reference-count":136,"publisher":"Bentham Science Publishers Ltd.","issue":"33","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CPD"],"published-print":{"date-parts":[[2019,11,19]]},"abstract":"<jats:sec>\n                    <jats:title>:<\/jats:title>\n                    <jats:p>Alzheimer\u2019s disease (AD) is a progressive neurodegenerative disease that causes problems with memory,\nthinking, and behavior. Currently, there is no drug that can reduce the pathological events of this degenerative\ndisease but symptomatic relief is possible that can abate the disease condition. N-methyl-D-aspartate\n(NMDA) receptors exert a critical role for synaptic plasticity as well as transmission. Overstimulation of glutamate\nreceptors, predominantly NMDA type, may cause excitotoxic effects on neurons and is recommended as a\nmechanism for neurodegeneration. Atypical activation of the NMDA receptor has been suggested for AD by\nsynaptic dysfunction. NMDA receptor antagonists especially memantine block the NMDA receptor and can reduce\nthe influx of calcium (Ca2+) ions into neuron, thus, toxic intracellular events are not activated. This review\nrepresents the role of NMDA receptors antagonists as potential therapeutic agents to reduce AD. Moreover, this\nreview highlights the repositioning of memantine as a potential novel therapeutic multitargeting agent for AD.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.2174\/1381612825666191011102444","type":"journal-article","created":{"date-parts":[[2019,10,12]],"date-time":"2019-10-12T04:05:16Z","timestamp":1570853116000},"page":"3506-3518","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":113,"title":["NMDA Receptor Antagonists: Repositioning of Memantine as a Multitargeting Agent for Alzheimer's Therapy"],"prefix":"10.2174","volume":"25","author":[{"given":"Md. Tanvir","family":"Kabir","sequence":"first","affiliation":[{"name":"Department of Pharmacy, BRAC University, Dhaka, Bangladesh"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad A.","family":"Sufian","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, East West University, Dhaka, Bangladesh"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Md. Sahab","family":"Uddin","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Southeast University, Dhaka, Bangladesh"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mst. Marium","family":"Begum","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, East West University, Dhaka, Bangladesh"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shammi","family":"Akhter","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Southeast University, Dhaka, Bangladesh"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ariful","family":"Islam","sequence":"additional","affiliation":[{"name":"Department of Cell Biology and Neuroscience, Rowan University School of Osteopathic Medicine, Stratford, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bijo","family":"Mathew","sequence":"additional","affiliation":[{"name":"Division of Drug Design and Medicinal Chemistry Research Lab, Department of Pharmaceutical Chemistry, Ahalia School of Pharmacy, Palakkad, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Md. Siddiqul","family":"Islam","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Southeast University, Dhaka, Bangladesh"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Md. Shah","family":"Amran","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Chemistry, University of Dhaka, Dhaka, Bangladesh"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ghulam","family":"Md. Ashraf","sequence":"additional","affiliation":[{"name":"King Fahd Medical Research Center, King Abdulaziz University, Jeddah, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1111\/psyg.12368","volume":"19","author":"Uddin M.S.","year":"2019","unstructured":"Uddin M.S.; Al Mamun A.; Takeda S.; Analyzing the chance of developing dementia among geriatric people: a cross-sectional pilot study in Bangladesh. Psychogeriatrics 2019,19(2),87-94","journal-title":"Psychogeriatrics"},{"key":"ref=2","doi-asserted-by":"publisher","DOI":"10.5772\/intechopen.78252","author":"Ashraf G.M.","year":"2019","unstructured":"Ashraf G.M.; Uddin M.S.;  Advances in Dementia Research 2019","journal-title":"Advances in Dementia Research"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1016\/j.jalz.2017.02.001","volume":"13","year":"2017","unstructured":"Alzheimer\u2019s disease facts and figures. Alzheimers Dement Alzheimer\u2019s Association2017,13,325-373","journal-title":"Alzheimers Dement"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.3233\/JAD-160763","volume":"57","author":"Wang R.","year":"2017","unstructured":"Wang R.; Reddy P.H.; Role of glutamate and NMDA receptors in Alzheimer\u2019s disease. J Alzheimers Dis 2017,57(4),1041-1048","journal-title":"J Alzheimers Dis"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4172\/2155-9562.1000397","volume":"07","author":"Uddin M.S.","year":"2016","unstructured":"Uddin M.S.; Haque A.; Al Mamun A.; Searching the linkage between high fat diet and Alzheimer\u2032s disease: a debatable proof stand for ketogenic diet to alleviate symptoms of alzheimer\u2032s patient with APOE \u03b54 allele. J Neurol Neurophysiol 2016,07,1-9","journal-title":"J Neurol Neurophysiol"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1007\/s10072-016-2546-5","volume":"37","author":"Zhang Y.","year":"2016","unstructured":"Zhang Y.; Li P.; Feng J.; Wu M.; Dysfunction of NMDA receptors in Alzheimer\u2019s disease. Neurol Sci 2016,37(7),1039-1047","journal-title":"Neurol Sci"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"26","DOI":"10.11648\/j.ajpn.20160402.12","volume":"4","author":"Uddin M.S.","year":"2016","unstructured":"Uddin M.S.; Nasrullah M.; Hossain M.S.; Evaluation of nootropic activity of persicaria flaccida on cognitive performance, brain antioxidant markers and acetylcholinesterase activity in rats: implication for the management of Alzheimer\u2019s disease. Am J Psychiatry Neurosci 2016,4,26","journal-title":"Am J Psychiatry Neurosci"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"137","DOI":"10.6000\/2292-2598.2017.05.04.6","volume":"5","author":"Uddin M.S.","year":"2018","unstructured":"Uddin M.S.; Mamun A Al.; Kabir M.T.; Neurochemistry of Neurochemicals: Messengers of Brain Functions. J Intellect Disabil Diagnosis Treat 2018,5,137-151","journal-title":"J Intellect Disabil Diagnosis Treat"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.21767\/2171-6625.1000126","volume":"7","author":"Mamum A.A.","year":"2016","unstructured":"Mamum A.A.; Uddin M.S.; Wahid F.; Neurodefensive effect of Olea europaea L. in alloxan-induced cognitive dysfunction and brain tissue oxidative stress in mice: incredible natural nootropic. J Neurol Neurosci 2016,7,S3","journal-title":"J Neurol Neurosci"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1159\/000449482","volume":"23","author":"Uddin M.S.","year":"2016","unstructured":"Uddin M.S.; Mamun A.A.; Hossain M.S.; Akter F.; Iqbal M.A.; Asaduzzaman M.; Exploring the effect of Phyllanthus emblica L. on cognitive performance, brain antioxidant markers and acetylcholinesterase activity in rats: promising natural gift for the mitigation of Alzheimer\u2019s disease. Ann Neurosci 2016,23(4),218-229","journal-title":"Ann Neurosci"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1159\/000481812","volume":"25","author":"Uddin M.S.","year":"2018","unstructured":"Uddin M.S.; Al Mamun A.; Asaduzzaman M.; Spectrum of disease and prescription pattern for outpatients with neurological disorders: an empirical pilot study in Bangladesh. Ann Neurosci 2018,25(1),25-37","journal-title":"Ann Neurosci"},{"key":"ref=12","unstructured":"Alzheimer Disease International Dementia statistics: Numbers of people with dementia. Accessed on: 15 Jul 2019."},{"key":"ref=13","first-page":"1","author":"Prince M.","year":"2013","unstructured":"Prince M.; Guerchet M.; Prina M.;  The Global impact of dementia 2013-2050 policy brief for heads of government 2013,1-8","journal-title":"The Global impact of dementia 2013-2050 policy brief for heads of government"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"87","DOI":"10.4236\/aad.2016.53007","volume":"05","author":"Uddin M.S.","year":"2016","unstructured":"Uddin M.S.; Al Mamun A.; Iqbal M.A.; Analyzing nootropic effect of Phyllanthus reticulatus Poir. on cognitive functions, brain antioxidant enzymes and acetylcholinesterase activity against aluminium-induced Alzheimer\u2019s model in rats: applicable for controlling the risk factors of alzheimer\u2019s disease. Adv Alzheimer Dis 2016,05,87-102","journal-title":"Adv Alzheimer Dis"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4172\/2161-0460.1000245","volume":"6","author":"Uddin M.S.","year":"2016","unstructured":"Uddin M.S.; Asaduzzaman M.; Neuroprotective activity of Asparagus racemosus Linn. against ethanol- induced cognitive impairment and oxidative stress in rats brain: auspicious for controlling the risk of Alzheimer\u2019s disease. J Alzheimer\u2019s Dis Park 2016,6,1-10","journal-title":"J Alzheimer\u2019s Dis Park"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"50","DOI":"10.6000\/2292-2598.2017.05.02.3","volume":"5","author":"Rahman A.","year":"2017","unstructured":"Rahman A.; Haque A.; Uddin M.; \n                        In vitro screening for antioxidant and anticholinesterase effects of Uvaria littoralis Blume.: a nootropic phytotherapeutic remedy. J Intellect Disabil-Diagnosis Treat 2017,5,50-60","journal-title":"J Intellect Disabil-Diagnosis Treat"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2174\/1381612825666191008103141","volume":"25","author":"Kabir M.T.","year":"2019","unstructured":"Kabir M.T.; Uddin M.S.; Begum M.M.; Cholinesterase inhibitors for Alzheimer\u2019s disease: multitargeting strategy based on anti-alzheimer\u2019s drugs repositioning. Curr Pharm Des 2019,25,1-17","journal-title":"Curr Pharm Des"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1056\/NEJMra040223","volume":"351","author":"Cummings J.L.","year":"2004","unstructured":"Cummings J.L.; Alzheimer\u2019s disease. N Engl J Med 2004,351(1),56-67","journal-title":"N Engl J Med"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"53","DOI":"10.4236\/aad.2016.52005","volume":"05","author":"Uddin M.S.","year":"2016","unstructured":"Uddin M.S.; Al Mamun A.; Hossain M.S.; Neuroprotective effect of Phyllanthus acidus L. on learning and memory impairment in scopolamine-induced animal model of dementia and oxidative stress: natural wonder for regulating the development and progression of Alzheimer\u2019s disease. Adv Alzheimer Dis 2016,05,53-72","journal-title":"Adv Alzheimer Dis"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1111\/j.1471-4159.2004.02548.x","volume":"90","author":"Hynd M.R.","year":"2004","unstructured":"Hynd M.R.; Scott H.L.; Dodd P.R.; Differential expression of N-methyl-D-aspartate receptor NR2 isoforms in Alzheimer\u2019s disease. J Neurochem 2004,90(4),913-919","journal-title":"J Neurochem"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1177\/1073858402008003013","volume":"8","author":"Bamberger M.E.","year":"2002","unstructured":"Bamberger M.E.; Landreth G.E.; Inflammation, apoptosis, and Alzheimer\u2019s disease. Neuroscientist 2002,8(3),276-283","journal-title":"Neuroscientist"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s12035-019-01660-3","author":"Hossain M.F.","year":"2019","unstructured":"Hossain M.F.; Uddin M.S.; Uddin G.M.S.; Melatonin in Alzheimer\u2019s disease: a latent endogenous regulator of neurogenesis to mitigate alzheimer\u2019s neuropathology. Mol Neurobiol 2019,1-22","journal-title":"Mol Neurobiol"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"2450","DOI":"10.1007\/s12035-018-1237-z","volume":"56","author":"Uddin M.S.","year":"2019","unstructured":"Uddin M.S.; Kabir M.T.; Al Mamun A.; Abdel-Daim M.M.; Barreto G.E.; Ashraf G.M.; APOE and Alzheimer\u2019s disease: evidence mounts that targeting APOE4 may combat Alzheimer\u2019s pathogenesis. Mol Neurobiol 2019,56(4),2450-2465","journal-title":"Mol Neurobiol"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1126\/science.1072994","volume":"297","author":"Hardy J.","year":"2002","unstructured":"Hardy J.; Selkoe D.J.; The amyloid hypothesis of Alzheimer\u2019s disease: progress and problems on the road to therapeutics. Science 2002,297(5580),353-356","journal-title":"Science"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"473","DOI":"10.2174\/156720507781788882","volume":"4","author":"Aisen P.S.","year":"2007","unstructured":"Aisen P.S.; Gauthier S.; Vellas B.; Alzhemed: a potential treatment for Alzheimer\u2019s disease. Curr Alzheimer Res 2007,4(4),473-478","journal-title":"Curr Alzheimer Res"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.1074\/jbc.M507892200","volume":"281","author":"Oddo S.","year":"2006","unstructured":"Oddo S.; Caccamo A.; Tran L.; Temporal profile of amyloid-\u03b2 (Abeta) oligomerization in an in vivo model of Alzheimer disease. A link between Abeta and tau pathology. J Biol Chem 2006,281(3),1599-1604","journal-title":"J Biol Chem"},{"key":"ref=27","author":"Uddin M.S.","year":"2019","unstructured":"Uddin M.S.; Kabir M.T.; Oxidative stress in Alzheimer\u2019s disease: molecular hallmarks of underlying vulnerability. Ashraf G, Alexiou A (eds) Biological, Diagnostic and Therapeutic Advances in Alzheimer\u2019s Disease 2019","journal-title":"Ashraf G, Alexiou A (eds) Biological, Diagnostic and Therapeutic Advances in Alzheimer\u2019s Disease"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fcell.2019.00197","volume":"7","author":"Uddin M.S.","year":"2019","unstructured":"Uddin M.S.; Kabir M.T.; Emerging signal regulating potential of genistein against Alzheimer\u2019s Disease: a promising molecule of interest. Front Cell Dev Biol 2019,7,1-12","journal-title":"Front Cell Dev Biol"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1038\/nn.2583","volume":"13","author":"Palop J.J.","year":"2010","unstructured":"Palop J.J.; Mucke L.; Amyloid-\u03b2-induced neuronal dysfunction in Alzheimer\u2019s disease: from synapses toward neural networks. Nat Neurosci 2010,13(7),812-818","journal-title":"Nat Neurosci"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1016\/j.neuron.2007.07.025","volume":"55","author":"Palop J.J.","year":"2007","unstructured":"Palop J.J.; Chin J.; Roberson E.D.; Aberrant excitatory neuronal activity and compensatory remodeling of inhibitory hippocampal circuits in mouse models of Alzheimer\u2019s disease. Neuron 2007,55(5),697-711","journal-title":"Neuron"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"4277","DOI":"10.1523\/JNEUROSCI.5078-05.2006","volume":"26","author":"Almeida C.G.","year":"2006","unstructured":"Almeida C.G.; Takahashi R.H.; Gouras G.K.; Beta-amyloid accumulation impairs multivesicular body sorting by inhibiting the ubiquitin-proteasome system. J Neurosci 2006,26(16),4277-4288","journal-title":"J Neurosci"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1038\/nrn2168","volume":"8","author":"LaFerla F.M.","year":"2007","unstructured":"LaFerla F.M.; Green K.N.; Oddo S.; Intracellular amyloid-\u03b2 in Alzheimer\u2019s disease. Nat Rev Neurosci 2007,8(7),499-509","journal-title":"Nat Rev Neurosci"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"25056","DOI":"10.1074\/jbc.M200066200","volume":"277","author":"Dineley K.T.","year":"2002","unstructured":"Dineley K.T.; Bell K.A.; Bui D.; Sweatt J.D.; \u03b2 -Amyloid peptide activates \u03b1 7 nicotinic acetylcholine receptors expressed in Xenopus oocytes. J Biol Chem 2002,277(28),25056-25061","journal-title":"J Biol Chem"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"14537","DOI":"10.1523\/JNEUROSCI.2692-08.2008","volume":"28","author":"Puzzo D.","year":"2008","unstructured":"Puzzo D.; Privitera L.; Leznik E.; Picomolar amyloid-beta positively modulates synaptic plasticity and memory in hippocampus. J Neurosci 2008,28(53),14537-14545","journal-title":"J Neurosci"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"4925","DOI":"10.1007\/s12035-018-1420-2","volume":"56","author":"Uddin M.S.","year":"2019","unstructured":"Uddin M.S.; Al Mamun A.; Kabir M.T.; Nootropic and anti-Alzheimer\u2019s actions of medicinal plants: molecular insight into therapeutic potential to alleviate Alzheimer\u2019s neuropathology. Mol Neurobiol 2019,56(7),4925-4944","journal-title":"Mol Neurobiol"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"8094","DOI":"10.1002\/jcp.27588","volume":"234","author":"Uddin M.S.","year":"2019","unstructured":"Uddin M.S.; Al Mamun A.; Labu Z.K.; Autophagic dysfunction in Alzheimer\u2019s disease: cellular and molecular mechanistic approaches to halt Alzheimer\u2019s pathogenesis. J Cell Physiol 2019,234(6),8094-8112","journal-title":"J Cell Physiol"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fnagi.2018.00004","volume":"10","author":"Uddin M.S.","year":"2018","unstructured":"Uddin M.S.; Stachowiak A.; Mamun A.A.; Autophagy and Alzheimer\u2019s disease: from molecular mechanisms to therapeutic implications. Front Aging Neurosci 2018,10,1-18","journal-title":"Front Aging Neurosci"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1016\/j.bbadis.2004.09.008","volume":"1739","author":"Iqbal K.","year":"2005","unstructured":"Iqbal K.; Alonso Adel C.; Chen S.; Tau pathology in Alzheimer disease and other tauopathies. Biochim Biophys Acta 2005,1739(2-3),198-210","journal-title":"Biochim Biophys Acta"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1126\/science.1113694","volume":"309","author":"SantaCruz K","year":"2005","unstructured":"SantaCruz K; Lewis J; Spires T; Tau Suppression in a neurodegenerative mouse model improves memory function. Science (80- ) 2005,309,476-481","journal-title":"Science (80- )"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1046\/j.1471-4159.2003.01879.x","volume":"86","author":"Andorfer C.","year":"2003","unstructured":"Andorfer C.; Kress Y.; Espinoza M.; Hyperphosphorylation and aggregation of tau in mice expressing normal human tau isoforms. J Neurochem 2003,86(3),582-590","journal-title":"J Neurochem"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/j.molmed.2005.02.008","volume":"11","author":"Lee H.G.","year":"2005","unstructured":"Lee H.G.; Perry G.; Moreira P.I.; Tau phosphorylation in Alzheimer\u2019s disease: pathogen or protector? Trends Mol Med 2005,11(4),164-169","journal-title":"Trends Mol Med"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1126\/science.1141736","volume":"316","author":"Roberson E.D.","year":"2007","unstructured":"Roberson E.D.; Scearce-Levie K.; Palop J.J.; Reducing endogenous tau ameliorates amyloid-induced deficits in an Alzheimer\u2019s disease mouse model. Science 2007,316,750-754","journal-title":"Science"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"3650","DOI":"10.1523\/JNEUROSCI.0587-07.2007","volume":"27","author":"Berger Z.","year":"2007","unstructured":"Berger Z.; Roder H.; Hanna A.; Accumulation of pathological tau species and memory loss in a conditional model of tauopathy. J Neurosci 2007,27(14),3650-3662","journal-title":"J Neurosci"},{"key":"ref=44","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1007\/s00401-012-1038-9","volume":"124","author":"Crimins J.L.","year":"2012","unstructured":"Crimins J.L.; Rocher A.B.; Luebke J.I.; Electrophysiological changes precede morphological changes to frontal cortical pyramidal neurons in the rTg4510 mouse model of progressive tauopathy. Acta Neuropathol 2012,124(6),777-795","journal-title":"Acta Neuropathol"},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1016\/j.expneurol.2009.07.029","volume":"223","author":"Rocher A.B.","year":"2010","unstructured":"Rocher A.B.; Crimins J.L.; Amatrudo J.M.; Structural and functional changes in tau mutant mice neurons are not linked to the presence of NFTs. Exp Neurol 2010,223(2),385-393","journal-title":"Exp Neurol"},{"key":"ref=46","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1016\/j.neuron.2010.11.030","volume":"68","author":"Hoover B.R.","year":"2010","unstructured":"Hoover B.R.; Reed M.N.; Su J.; Tau mislocalization to dendritic spines mediates synaptic dysfunction independently of neurodegeneration. Neuron 2010,68(6),1067-1081","journal-title":"Neuron"},{"key":"ref=47","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.bbr.2008.02.016","volume":"192","author":"Selkoe D.J.","year":"2008","unstructured":"Selkoe D.J.; Soluble oligomers of the amyloid beta-protein impair synaptic plasticity and behavior. Behav Brain Res 2008,192(1),106-113","journal-title":"Behav Brain Res"},{"key":"ref=48","doi-asserted-by":"publisher","first-page":"233","DOI":"10.2174\/156720508784533321","volume":"5","author":"Cerpa W.","year":"2008","unstructured":"Cerpa W.; Dinamarca M.C.; Inestrosa N.C.; Structure-function implications in Alzheimer\u2019s disease: effect of Abeta oligomers at central synapses. Curr Alzheimer Res 2008,5(3),233-243","journal-title":"Curr Alzheimer Res"},{"key":"ref=49","author":"Uddin M.S.","year":"2018","unstructured":"Uddin M.S.; Amran M.S.;  Handbook of Research on Critical Examinations of Neurodegenerative Disorders 2018","journal-title":"Handbook of Research on Critical Examinations of Neurodegenerative Disorders"},{"key":"ref=50","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1016\/j.neuron.2009.05.012","volume":"62","author":"Li S.","year":"2009","unstructured":"Li S.; Hong S.; Shepardson N.E.; Walsh D.M.; Shankar G.M.; Selkoe D.; Soluble oligomers of amyloid Beta protein facilitate hippocampal long-term depression by disrupting neuronal glutamate uptake. Neuron 2009,62(6),788-801","journal-title":"Neuron"},{"key":"ref=51","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1016\/S0301-0082(97)00055-5","volume":"54","author":"Michaelis E.K.","year":"1998","unstructured":"Michaelis E.K.; Molecular biology of glutamate receptors in the central nervous system and their role in excitotoxicity, oxidative stress and aging. Prog Neurobiol 1998,54(4),369-415","journal-title":"Prog Neurobiol"},{"key":"ref=52","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1186\/s40478-014-0146-2","volume":"2","author":"Tai H-C.","year":"2014","unstructured":"Tai H-C.; Wang B.Y.; Serrano-Pozo A.; Frosch M.P.; Spires-Jones T.L.; Hyman B.T.; Frequent and symmetric deposition of misfolded tau oligomers within presynaptic and postsynaptic terminals in Alzheimer\u2019s disease. Acta Neuropathol Commun 2014,2,146","journal-title":"Acta Neuropathol Commun"},{"key":"ref=53","doi-asserted-by":"publisher","first-page":"6084","DOI":"10.1523\/JNEUROSCI.4261-13.2014","volume":"34","author":"Frandemiche M.L.","year":"2014","unstructured":"Frandemiche M.L.; De Seranno S.; Rush T.; Activity-dependent tau protein translocation to excitatory synapse is disrupted by expo-sure to amyloid-beta oligomers. J Neurosci 2014,34(17),6084-6097","journal-title":"J Neurosci"},{"key":"ref=54","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.nbd.2014.01.007","volume":"64","author":"Chabrier M.A.","year":"2014","unstructured":"Chabrier M.A.; Cheng D.; Castello N.A.; Green K.N.; LaFerla F.M.; Synergistic effects of amyloid-beta and wild-type human tau on dendritic spine loss in a floxed double transgenic model of Alzheimer\u2019s disease. Neurobiol Dis 2014,64,107-117","journal-title":"Neurobiol Dis"},{"key":"ref=55","doi-asserted-by":"publisher","first-page":"6103","DOI":"10.1523\/JNEUROSCI.4245-05.2006","volume":"26","author":"Shahani N.","year":"2006","unstructured":"Shahani N.; Subramaniam S.; Wolf T.; Tackenberg C.; Brandt R.; Tau aggregation and progressive neuronal degeneration in the absence of changes in spine density and morphology after targeted expression of Alzheimer\u2019s disease-relevant tau constructs in organotypic hippocampal slices. J Neurosci 2006,26(22),6103-6114","journal-title":"J Neurosci"},{"key":"ref=56","doi-asserted-by":"publisher","first-page":"14439","DOI":"10.1523\/JNEUROSCI.3590-09.2009","volume":"29","author":"Tackenberg C.","year":"2009","unstructured":"Tackenberg C.; Brandt R.; Divergent pathways mediate spine alterations and cell death induced by amyloid-beta, wild-type tau, and R406W tau. J Neurosci 2009,29(46),14439-14450","journal-title":"J Neurosci"},{"key":"ref=57","doi-asserted-by":"publisher","first-page":"e608","DOI":"10.1038\/cddis.2013.129","volume":"4","author":"Tackenberg C.","year":"2013","unstructured":"Tackenberg C.; Grinschgl S.; Trutzel A.; NMDA receptor subunit composition determines beta-amyloid-induced neurodegeneration and synaptic loss. Cell Death Dis 2013,4,e608-e8","journal-title":"Cell Death Dis"},{"key":"ref=58","doi-asserted-by":"publisher","first-page":"3","DOI":"10.3389\/fnsyn.2011.00003","volume":"3","author":"Moreno H.","year":"2011","unstructured":"Moreno H.; Choi S.; Yu E.; Blocking effects of human tau on squid giant synapse transmission and its prevention by T-817 MA. Front Synaptic Neurosci 2011,3,3","journal-title":"Front Synaptic Neurosci"},{"key":"ref=59","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1100\/2012\/267120","volume":"2012","author":"Petralia R.S.","year":"2012","unstructured":"Petralia R.S.; Distribution of extrasynaptic NMDA receptors on neurons. ScientificWorldJournal 2012,2012,1-11","journal-title":"ScientificWorldJournal"},{"key":"ref=60","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/alzrt75","volume":"3","author":"Piette F.","year":"2011","unstructured":"Piette F.; Belmin J.; Vincent H.; Masitinib as an adjunct therapy for mild-to-moderate Alzheimer\u2019s disease: a randomised, placebo-controlled phase 2 trial. Alzheimers Res Ther 2011,3(2),16","journal-title":"Alzheimers Res Ther"},{"key":"ref=61","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1007\/s00441-013-1789-1","volume":"356","author":"Rush T.","year":"2014","unstructured":"Rush T.; Buisson A.; Reciprocal disruption of neuronal signaling and A\u03b2 production mediated by extrasynaptic NMDA receptors: a downward spiral. Cell Tissue Res 2014,356(2),279-286","journal-title":"Cell Tissue Res"},{"key":"ref=62","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1515\/rns.2011.029","volume":"22","author":"Bordji K.","year":"2011","unstructured":"Bordji K.; Becerril-Ortega J.; Buisson A.; Synapses, NMDA receptor activity and neuronal A\u03b2 production in Alzheimer\u2019s disease. Rev Neurosci 2011,22(3),285-294","journal-title":"Rev Neurosci"},{"key":"ref=63","doi-asserted-by":"publisher","first-page":"4258","DOI":"10.1096\/fj.08-107268","volume":"22","author":"L\u00e9veill\u00e9 F.","year":"2008","unstructured":"L\u00e9veill\u00e9 F.; El Gaamouch F.; Gouix E.; Neuronal viability is controlled by a functional relation between synaptic and extrasynaptic NMDA receptors. FASEB J 2008,22(12),4258-4271","journal-title":"FASEB J"},{"key":"ref=64","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1007\/s00441-013-1789-1","volume":"356","author":"Rush T.","year":"2014","unstructured":"Rush T.; Buisson A.; Reciprocal disruption of neuronal signaling and A\u03b2 production mediated by extrasynaptic NMDA receptors: a downward spiral. Cell Tissue Res 2014,356(2),279-286","journal-title":"Cell Tissue Res"},{"key":"ref=65","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1515\/rns.2011.029","volume":"22","author":"Bordji K.","year":"2011","unstructured":"Bordji K.; Becerril-Ortega J.; Buisson A.; Synapses, NMDA receptor activity and neuronal A\u03b2 production in Alzheimer\u2019s disease. Rev Neurosci 2011,22(3),285-294","journal-title":"Rev Neurosci"},{"key":"ref=66","doi-asserted-by":"publisher","first-page":"4258","DOI":"10.1096\/fj.08-107268","volume":"22","author":"L\u00e9veill\u00e9 F.","year":"2008","unstructured":"L\u00e9veill\u00e9 F.; El Gaamouch F.; Gouix E.; Neuronal viability is controlled by a functional relation between synaptic and extrasynaptic NMDA receptors. FASEB J 2008,22(12),4258-4271","journal-title":"FASEB J"},{"key":"ref=67","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1038\/nrn3504","volume":"14","author":"Paoletti P.","year":"2013","unstructured":"Paoletti P.; Bellone C.; Zhou Q.; NMDA receptor subunit diversity: impact on receptor properties, synaptic plasticity and disease. Nat Rev Neurosci 2013,14(6),383-400","journal-title":"Nat Rev Neurosci"},{"key":"ref=68","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1038\/nrn2911","volume":"11","author":"Hardingham G.E.","year":"2010","unstructured":"Hardingham G.E.; Bading H.; Synaptic versus extrasynaptic NMDA receptor signalling: implications for neurodegenerative disorders. Nat Rev Neurosci 2010,11(10),682-696","journal-title":"Nat Rev Neurosci"},{"key":"ref=69","doi-asserted-by":"publisher","first-page":"10242","DOI":"10.1038\/ncomms10242","volume":"7","author":"Akhtar M.W.","year":"2016","unstructured":"Akhtar M.W.; Sanz-Blasco S.; Dolatabadi N.; Elevated glucose and oligomeric \u03b2-amyloid disrupt synapses via a common pathway of aberrant protein S-nitrosylation. Nat Commun 2016,7,10242","journal-title":"Nat Commun"},{"key":"ref=70","doi-asserted-by":"publisher","first-page":"15056","DOI":"10.1038\/nrdp.2015.56","volume":"1","author":"Masters C.L.","year":"2015","unstructured":"Masters C.L.; Bateman R.; Blennow K.; Rowe C.C.; Sperling R.A.; Cummings J.L.; Alzheimer\u2019s disease. Nat Rev Dis Primers 2015,1,15056","journal-title":"Nat Rev Dis Primers"},{"key":"ref=71","doi-asserted-by":"publisher","first-page":"155","DOI":"10.2174\/1567205053585846","volume":"2","author":"Lipton S.A.","year":"2005","unstructured":"Lipton S.A.; The molecular basis of memantine action in Alzheimer\u2019s disease and other neurologic disorders: low-affinity, uncompetitive antagonism. Curr Alzheimer Res 2005,2(2),155-165","journal-title":"Curr Alzheimer Res"},{"key":"ref=72","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1038\/nrn2229","volume":"8","author":"Lipton S.A.","year":"2007","unstructured":"Lipton S.A.; Pathologically activated therapeutics for neuroprotection. Nat Rev Neurosci 2007,8(10),803-808","journal-title":"Nat Rev Neurosci"},{"key":"ref=73","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1038\/309261a0","volume":"309","author":"Mayer M.L.","year":"1984","unstructured":"Mayer M.L.; Westbrook G.L.; Guthrie P.B.; Voltage-dependent block by Mg of NMDA responses in spinal cord neurones. Nature 1984,309(5965),261-263","journal-title":"Nature"},{"key":"ref=74","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1038\/307462a0","volume":"307","author":"Nowak L.","year":"1984","unstructured":"Nowak L.; Bregestovski P.; Ascher P.; Herbet A.; Prochiantz A.; Magnesium gates glutamate-activated channels in mouse central neurones. Nature 1984,307(5950),462-465","journal-title":"Nature"},{"key":"ref=75","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1038\/305719a0","volume":"305","author":"Lynch G.","year":"1983","unstructured":"Lynch G.; Larson J.; Kelso S.; Barrionuevo G.; Schottler F.; Intracellular injections of EGTA block induction of hippocampal long-term potentiation. Nature 1983,305(5936),719-721","journal-title":"Nature"},{"key":"ref=76","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1124\/pr.109.002451","volume":"62","author":"Traynelis S.F.","year":"2010","unstructured":"Traynelis S.F.; Wollmuth L.P.; McBain C.J.; Glutamate receptor ion channels: structure, regulation, and function. Pharmacol Rev 2010,62(3),405-496","journal-title":"Pharmacol Rev"},{"key":"ref=77","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1101\/lm.1398709","volume":"16","author":"M\u00fcller T.","year":"2009","unstructured":"M\u00fcller T.; Albrecht D.; Gebhardt C.; Both NR2A and NR2B subunits of the NMDA receptor are critical for long-term potentiation and long-term depression in the lateral amygdala of horizontal slices of adult mice. Learn Mem 2009,16(6),395-405","journal-title":"Learn Mem"},{"key":"ref=78","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1615\/CritRevNeurobiol.v18.i1-2.80","volume":"18","author":"MacDonald J.F.","year":"2006","unstructured":"MacDonald J.F.; Jackson M.F.; Beazely M.A.; Hippocampal long-term synaptic plasticity and signal amplification of NMDA receptors. Crit Rev Neurobiol 2006,18(1-2),71-84","journal-title":"Crit Rev Neurobiol"},{"key":"ref=79","doi-asserted-by":"publisher","first-page":"1369","DOI":"10.1042\/BST0371369","volume":"37","author":"Lau C.G.","year":"2009","unstructured":"Lau C.G.; Takeuchi K.; Rodenas-Ruano A.; Regulation of NMDA receptor Ca signalling and synaptic plasticity. Biochem Soc Trans 2009,37(Pt 6),1369-1374","journal-title":"Biochem Soc Trans"},{"key":"ref=80","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1111\/j.1460-9568.2011.07628.x","volume":"33","author":"Paoletti P.","year":"2011","unstructured":"Paoletti P.; Molecular basis of NMDA receptor functional diversity. Eur J Neurosci 2011,33(8),1351-1365","journal-title":"Eur J Neurosci"},{"key":"ref=81","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/S0006-3223(96)00047-9","volume":"41","author":"Kornhuber J.","year":"1997","unstructured":"Kornhuber J.; Weller M.; Psychotogenicity and N-methyl-D-aspartate receptor antagonism: implications for neuroprotective pharmacotherapy. Biol Psychiatry 1997,41(2),135-144","journal-title":"Biol Psychiatry"},{"key":"ref=82","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1038\/sj.mp.4001551","volume":"9","author":"Javitt DC","year":"2004","unstructured":"Javitt DC; Glutamate as a therapeutic target in psychiatric disorders. Mol Psychiatry 2004,9(11),984-997, 979","journal-title":"Mol Psychiatry"},{"key":"ref=83","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/0304-3940(95)11785-U","volume":"195","author":"Kornhuber J.","year":"1995","unstructured":"Kornhuber J.; Quack G.; Cerebrospinal fluid and serum concentrations of the N-methyl-D-aspartate (NMDA) receptor antagonist memantine in man. Neurosci Lett 1995,195(2),137-139","journal-title":"Neurosci Lett"},{"key":"ref=84","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1016\/0165-0173(94)00014-G","volume":"20","author":"Ellison G.","year":"1995","unstructured":"Ellison G.; The N-methyl-D-aspartate antagonists phencyclidine, ketamine and dizocilpine as both behavioral and anatomical models of the dementias. Brain Res Brain Res Rev 1995,20(2),250-267","journal-title":"Brain Res Brain Res Rev"},{"key":"ref=85","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1056\/NEJMoa013128","volume":"348","author":"Reisberg B.","year":"2003","unstructured":"Reisberg B.; Doody R.; St\u00f6ffler A.; Schmitt F.; Ferris S.; M\u00f6bius H.J.; Memantine in moderate-to-severe Alzheimer\u2019s disease. N Engl J Med 2003,348(14),1333-1341","journal-title":"N Engl J Med"},{"key":"ref=86","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1002\/acn3.39","volume":"1","author":"Pierson T.M.","year":"2014","unstructured":"Pierson T.M.; Yuan H.; Marsh E.D.; PhD for the NISC Comparative Sequencing Program. GRIN2A mutation and early-onset epileptic encephalopathy: personalized therapy with memantine. Ann Clin Transl Neurol 2014,1(3),190-198","journal-title":"Ann Clin Transl Neurol"},{"key":"ref=87","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1038\/s41586-018-0039-9","volume":"556","author":"Song X.","year":"2018","unstructured":"Song X.; Jensen M.\u00d8.; Jogini V.; Mechanism of NMDA receptor channel block by MK-801 and memantine. Nature 2018,556(7702),515-519","journal-title":"Nature"},{"key":"ref=88","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1146\/annurev-med-042915-103753","volume":"68","author":"Graham W.V.","year":"2017","unstructured":"Graham W.V.; Bonito-Oliva A.; Sakmar T.P.; Update on Alzheimer\u2019s disease therapy and prevention strategies. Annu Rev Med 2017,68,413-430","journal-title":"Annu Rev Med"},{"key":"ref=89","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.phrs.2004.05.005","volume":"51","author":"Sonkusare S.K.","year":"2005","unstructured":"Sonkusare S.K.; Kaul C.L.; Ramarao P.; Dementia of Alzheimer\u2019s disease and other neurodegenerative disorders-memantine, a new hope. Pharmacol Res 2005,51(1),1-17","journal-title":"Pharmacol Res"},{"key":"ref=90","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD003154.pub3","author":"Areosa S.A.","year":"2005","unstructured":"Areosa S.A.; Sherriff F.; McShane R.; Memantine for dementia. Cochrane Database Syst Rev 2005(2)","journal-title":"Cochrane Database Syst Rev"},{"key":"ref=91","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.coph.2005.09.007","volume":"6","author":"Johnson J.W.","year":"2006","unstructured":"Johnson J.W.; Kotermanski S.E.; Mechanism of action of memantine. Curr Opin Pharmacol 2006,6(1),61-67","journal-title":"Curr Opin Pharmacol"},{"key":"ref=92","doi-asserted-by":"publisher","first-page":"245","DOI":"10.2147\/nedt.2007.3.2.245","volume":"3","author":"Tampi R.R.","year":"2007","unstructured":"Tampi R.R.; van Dyck C.H.; Memantine: efficacy and safety in mild-to-severe Alzheimer\u2019s disease. Neuropsychiatr Dis Treat 2007,3(2),245-258","journal-title":"Neuropsychiatr Dis Treat"},{"key":"ref=93","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1046\/j.1471-4159.1995.64020614.x","volume":"64","author":"Porter R.H.P.","year":"1995","unstructured":"Porter R.H.P.; Greenamyre J.T.; Regional variations in the pharmacology of NMDA receptor channel blockers: implications for therapeutic potential. J Neurochem 1995,64(2),614-623","journal-title":"J Neurochem"},{"key":"ref=94","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1016\/S0028-3908(99)00019-2","volume":"38","author":"Parsons C.G.","year":"1999","unstructured":"Parsons C.G.; Danysz W.; Quack G.; Memantine is a clinically well tolerated N-methyl-D-aspartate (NMDA) receptor antagonist--a review of preclinical data. Neuropharmacology 1999,38(6),735-767","journal-title":"Neuropharmacology"},{"key":"ref=95","doi-asserted-by":"publisher","first-page":"129","DOI":"10.3109\/10799899909036640","volume":"19","author":"Ametamey S.M.","year":"1999","unstructured":"Ametamey S.M.; Samnick S.; Leenders K.L.; Fluorine-18 radiolabelling, biodistribution studies and preliminary PET evaluation of a new memantine derivative for imaging the NMDA receptor. J Recept Signal Transduct Res 1999,19(1-4),129-141","journal-title":"J Recept Signal Transduct Res"},{"key":"ref=96","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1046\/j.1365-2125.1998.00819.x","volume":"46","author":"Freudenthaler S.","year":"1998","unstructured":"Freudenthaler S.; Meineke I.; Schreeb K.H.; Boakye E.; Gundert-Remy U.; Gleiter C.H.; Influence of urine pH and urinary flow on the renal excretion of memantine. Br J Clin Pharmacol 1998,46(6),541-546","journal-title":"Br J Clin Pharmacol"},{"key":"ref=97","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/S0304-3940(03)00398-7","volume":"343","author":"Peeters M.","year":"2003","unstructured":"Peeters M.; Maloteaux J-M.; Hermans E.; Distinct effects of amantadine and memantine on dopaminergic transmission in the rat striatum. Neurosci Lett 2003,343(3),205-209","journal-title":"Neurosci Lett"},{"key":"ref=98","first-page":"543","volume":"290","author":"Hesselink M.B.","year":"1999","unstructured":"Hesselink M.B.; Smolders H.; Eilbacher B.; De Boer A.G.; Breimer D.D.; Danysz W.; The role of probenecid-sensitive organic acid transport in the pharmacokinetics of N-methyl-D-aspartate receptor antagonists acting at the glycine(B)-site: microdialysis and maximum electroshock seizures studies. J Pharmacol Exp Ther 1999,290(2),543-550","journal-title":"J Pharmacol Exp Ther"},{"key":"ref=99","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1016\/S0149-2918(04)90064-1","volume":"26","author":"Standridge J.B.","year":"2004","unstructured":"Standridge J.B.; Pharmacotherapeutic approaches to the treatment of Alzheimer\u2019s disease. Clin Ther 2004,26(5),615-630","journal-title":"Clin Ther"},{"key":"ref=100","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1002\/(SICI)1099-1166(199902)14:2<135:AID-GPS906>3.0.CO;2-0","volume":"14","author":"Winblad B.","year":"1999","unstructured":"Winblad B.; Poritis N.; Memantine in severe dementia: results of the 9M-Best Study (Benefit and efficacy in severely demented patients during treatment with memantine). Int J Geriatr Psychiatry 1999,14(2),135-146","journal-title":"Int J Geriatr Psychiatry"},{"key":"ref=101","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1097\/01.JGP.0000224350.82719.83","volume":"14","author":"Peskind E.R.","year":"2006","unstructured":"Peskind E.R.; Potkin S.G.; Pomara N.; Memantine treatment in mild to moderate Alzheimer disease: a 24-week randomized, controlled trial. Am J Geriatr Psychiatry 2006,14(8),704-715","journal-title":"Am J Geriatr Psychiatry"},{"key":"ref=102","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.scitotenv.2019.134836","volume":"134836","author":"Uddin M.S.","year":"2019","unstructured":"Uddin M.S.; Kabir M.T.; Tewari D.; Mathew B.; Aleya L.; Emerging signal regulating potential of small molecule biflavonoids to combat neuropathological insults of Alzheimer\u2019s disease. Sci Total Environ 2019,134836,1-11","journal-title":"Sci Total Environ"},{"key":"ref=103","doi-asserted-by":"publisher","first-page":"379","DOI":"10.7326\/0003-4819-148-5-200803040-00009","volume":"148","author":"Raina P.","year":"2008","unstructured":"Raina P.; Santaguida P.; Ismaila A.; Effectiveness of cholinesterase inhibitors and memantine for treating dementia: evidence review for a clinical practice guideline. Ann Intern Med 2008,148(5),379-397","journal-title":"Ann Intern Med"},{"key":"ref=104","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1001\/archneurol.2011.69","volume":"68","author":"Schneider L.S.","year":"2011","unstructured":"Schneider L.S.; Dagerman K.S.; Higgins J.P.; McShane R.; Lack of evidence for the efficacy of memantine in mild Alzheimer disease. Arch Neurol 2011,68(8),991-998","journal-title":"Arch Neurol"},{"key":"ref=105","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1177\/193229680800200619","volume":"2","author":"de la Monte S.M.","year":"2008","unstructured":"de la Monte S.M.; Wands J.R.; Alzheimer\u2019s disease is type 3 diabetes-evidence reviewed. J Diabetes Sci Technol 2008,2(6),1101-1113","journal-title":"J Diabetes Sci Technol"},{"key":"ref=106","doi-asserted-by":"publisher","first-page":"2262","DOI":"10.2337\/db13-1954","volume":"63","author":"De Felice F.G.","year":"2014","unstructured":"De Felice F.G.; Ferreira S.T.; Inflammation, defective insulin signaling, and mitochondrial dysfunction as common molecular denominators connecting type 2 diabetes to Alzheimer disease. Diabetes 2014,63(7),2262-2272","journal-title":"Diabetes"},{"key":"ref=107","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.brainres.2017.03.029","volume":"1665","author":"Zhao H.","year":"2017","unstructured":"Zhao H.; Alam A.; San C-Y.; Molecular mechanisms of brain-derived neurotrophic factor in neuro-protection: Recent developments. Brain Res 2017,1665,1-21","journal-title":"Brain Res"},{"key":"ref=108","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1038\/nm.3822","volume":"21","author":"Marquard J.","year":"2015","unstructured":"Marquard J.; Otter S.; Welters A.; Characterization of pancreatic NMDA receptors as possible drug targets for diabetes treatment. Nat Med 2015,21(4),363-372","journal-title":"Nat Med"},{"key":"ref=109","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1111\/dom.12576","volume":"18","author":"Marquard J.","year":"2016","unstructured":"Marquard J.; Stirban A.; Schliess F.; Effects of dextromethorphan as add-on to sitagliptin on blood glucose and serum insulin concentrations in individuals with type 2 diabetes mellitus: a randomized, placebo-controlled, double-blinded, multiple crossover, single-dose clinical trial. Diabetes Obes Metab 2016,18(1),100-103","journal-title":"Diabetes Obes Metab"},{"key":"ref=110","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.1152\/physrev.00032.2015","volume":"96","author":"Kullmann S.","year":"2016","unstructured":"Kullmann S.; Heni M.; Hallschmid M.; Fritsche A.; Preissl H.; H\u00e4ring H.U.; Brain insulin resistance at the crossroads of metabolic and cognitive disorders in humans. Physiol Rev 2016,96(4),1169-1209","journal-title":"Physiol Rev"},{"key":"ref=111","doi-asserted-by":"publisher","first-page":"204","DOI":"10.3389\/fnins.2015.00204","volume":"9","author":"Bedse G.","year":"2015","unstructured":"Bedse G.; Di Domenico F.; Serviddio G.; Cassano T.; Aberrant insulin signaling in Alzheimer\u2019s disease: current knowledge. Front Neurosci 2015,9,204","journal-title":"Front Neurosci"},{"key":"ref=112","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s40336-013-0026-y","volume":"1","author":"Mosconi L.","year":"2013","unstructured":"Mosconi L.; Glucose metabolism in normal aging and Alzheimer's disease: Methodological and physiological considerations for PET studies. Clin Transl Imaging 2013,1(4),1-25.1007\/s40336-013- 0026-y","journal-title":"Clin Transl Imaging"},{"key":"ref=113","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1038\/nm.3822","volume":"21","author":"Marquard J.","year":"2015","unstructured":"Marquard J.; Otter S.; Welters A.; Characterization of pancreatic NMDA receptors as possible drug targets for diabetes treatment. Nat Med 2015,21(4),363-372","journal-title":"Nat Med"},{"key":"ref=114","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1111\/dom.12576","volume":"18","author":"Marquard J.","year":"2016","unstructured":"Marquard J.; Stirban A.; Schliess F.; Effects of dextromethorphan as add-on to sitagliptin on blood glucose and serum insulin concentrations in individuals with type 2 diabetes mellitus: a randomized, placebo-controlled, double-blinded, multiple crossover, single-dose clinical trial. Diabetes Obes Metab 2016,18(1),100-103","journal-title":"Diabetes Obes Metab"},{"key":"ref=115","doi-asserted-by":"publisher","first-page":"190","DOI":"10.15252\/emmm.201404183","volume":"7","author":"Clarke J.R.","year":"2015","unstructured":"Clarke J.R.; Lyra E.; Silva N.M.; Figueiredo C.P.; Alzheimer-associated A\u03b2 oligomers impact the central nervous system to induce peripheral metabolic deregulation. EMBO Mol Med 2015,7(2),190-210","journal-title":"EMBO Mol Med"},{"key":"ref=116","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1055\/s-0042-117831","volume":"229","author":"Welters A.","year":"2017","unstructured":"Welters A.; Lammert E.; Mayatepek E.; Meissner T.; Need for better diabetes treatment: the therapeutic potential of NMDA receptor antagonists. Klin Padiatr 2017,229(1),14-20","journal-title":"Klin Padiatr"},{"key":"ref=117","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1038\/nm.3835","volume":"21","author":"Wollheim C.B.","year":"2015","unstructured":"Wollheim C.B.; Maechler P.; Beta cell glutamate receptor antagonists: novel oral antidiabetic drugs? Nat Med 2015,21(4),310-311","journal-title":"Nat Med"},{"key":"ref=118","doi-asserted-by":"publisher","first-page":"7327","DOI":"10.1007\/s12035-018-0868-4","volume":"55","author":"Ettcheto M.","year":"2018","unstructured":"Ettcheto M.; S\u00e1nchez-L\u00f3pez E.; G\u00f3mez-M\u00ednguez Y.; Peripheral and central effects of memantine in a mixed preclinical mice model of obesity and familial Alzheimer\u2019s disease. Mol Neurobiol 2018,55(9),7327-7339","journal-title":"Mol Neurobiol"},{"key":"ref=119","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1602\/neurorx.1.1.101","volume":"1","author":"Lipton S.A.","year":"2004","unstructured":"Lipton S.A.; Failures and successes of NMDA receptor antagonists: molecular basis for the use of open-channel blockers like memantine in the treatment of acute and chronic neurologic insults. NeuroRx 2004,1(1),101-110","journal-title":"NeuroRx"},{"key":"ref=120","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.1016\/S0042-6989(98)00003-0","volume":"38","author":"Zurakowski D.","year":"1998","unstructured":"Zurakowski D.; Vorwerk C.K.; Gorla M.; Nitrate therapy may retard glaucomatous optic neuropathy, perhaps through modulation of glutamate receptors. Vision Res 1998,38(10),1489-1494","journal-title":"Vision Res"},{"key":"ref=121","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1016\/S0166-2236(02)02245-2","volume":"25","author":"Lipton S.A.","year":"2002","unstructured":"Lipton S.A.; Choi Y-B.; Takahashi H.; Cysteine regulation of protein function-as exemplified by NMDA-receptor modulation. Trends Neurosci 2002,25(9),474-480","journal-title":"Trends Neurosci"},{"key":"ref=122","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/S0079-6123(08)63201-X","volume":"118","author":"Lipton S.A.","year":"1998","unstructured":"Lipton S.A.; Rayudu P.V.; Choi Y.B.; Sucher N.J.; Chen H.S.;  Prog Brain Res 1998,118,73-82","journal-title":"Prog Brain Res"},{"key":"ref=123","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1038\/71090","volume":"3","author":"Choi Y-B.","year":"2000","unstructured":"Choi Y-B.; Tenneti L.; Le D.A.; Molecular basis of NMDA receptor-coupled ion channel modulation by S-nitrosylation. Nat Neurosci 2000,3(1),15-21","journal-title":"Nat Neurosci"},{"key":"ref=124","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1038\/364626a0","volume":"364","author":"Lipton S.A.","year":"1993","unstructured":"Lipton S.A.; Choi Y-B.; Pan Z-H.; A redox-based mechanism for the neuroprotective and neurodestructive effects of nitric oxide and related nitroso-compounds. Nature 1993,364(6438),626-632","journal-title":"Nature"},{"key":"ref=125","doi-asserted-by":"publisher","first-page":"3773","DOI":"10.1021\/jm5000613","volume":"57","author":"L\u00f3pez-Iglesias B.","year":"2014","unstructured":"L\u00f3pez-Iglesias B.; P\u00e9rez C.; Morales-Garc\u00eda J.A.; New melatonin-N,N-dibenzyl(N-methyl)amine hybrids: potent neurogenic agents with antioxidant, cholinergic, and neuroprotective properties as innovative drugs for Alzheimer\u2019s disease. J Med Chem 2014,57(9),3773-3785","journal-title":"J Med Chem"},{"key":"ref=126","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1254\/jphs.13042FP","volume":"123","author":"Yamaguchi Y.","year":"2013","unstructured":"Yamaguchi Y.; Takeda K.; Hino M.; Combination effects of ZSET1446\/ST101 with memantine on cognitive function and extracellular acetylcholine in the hippocampus. J Pharmacol Sci 2013,123(4),347-355","journal-title":"J Pharmacol Sci"},{"key":"ref=127","doi-asserted-by":"publisher","first-page":"124","DOI":"10.3389\/fpsyt.2013.00124","volume":"4","author":"Brem A-K.","year":"2013","unstructured":"Brem A-K.; Atkinson N.J.; Seligson E.E.; Pascual-Leone A.; Differential pharmacological effects on brain reactivity and plasticity in Alzheimer\u2019s disease. Front Psychiatry 2013,4,124","journal-title":"Front Psychiatry"},{"key":"ref=128","doi-asserted-by":"publisher","first-page":"641","DOI":"10.3233\/JAD-140016","volume":"41","author":"Mattace-Raso F.","year":"2014","unstructured":"Mattace-Raso F.; Is memantine+acetylcholinesterase inhibitor treatment superior to either therapy alone in Alzheimer\u2019s disease? J Alzheimers Dis 2014,41(2),641-642","journal-title":"J Alzheimers Dis"},{"key":"ref=129","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1002\/brb3.118","volume":"3","author":"Lopes J.P.","year":"2013","unstructured":"Lopes J.P.; Tarozzo G.; Reggiani A.; Piomelli D.; Cavalli A.; Galantamine potentiates the neuroprotective effect of memantine against NMDA-induced excitotoxicity. Brain Behav 2013,3(2),67-74","journal-title":"Brain Behav"},{"key":"ref=130","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1177\/0004867412464718","volume":"47","author":"Hamuro A.","year":"2013","unstructured":"Hamuro A.; Combination therapy with galantamine and memantine improves behavioral and psychological symptoms of dementia (BPSD) in patients with early-onset Alzheimer\u2019s disease. Aust N Z J Psychiatry 2013,47(6),583-3","journal-title":"Aust N Z J Psychiatry"},{"key":"ref=131","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1056\/NEJMoa1106668","volume":"366","author":"Howard R.","year":"2012","unstructured":"Howard R.; McShane R.; Lindesay J.; Donepezil and memantine for moderate-to-severe Alzheimer\u2019s disease. N Engl J Med 2012,366(10),893-903","journal-title":"N Engl J Med"},{"key":"ref=132","doi-asserted-by":"publisher","DOI":"10.1155\/2013\/925702","volume":"2013","author":"Molino I.","year":"2013","unstructured":"Molino I.; Colucci L.; Fasanaro A.M.; Traini E.; Amenta F.; Efficacy of memantine, donepezil, or their association in moderate-severe Alzheimer\u2019s disease: a review of clinical trials. ScientificWorldJournal 2013,2013","journal-title":"ScientificWorldJournal"},{"key":"ref=133","doi-asserted-by":"publisher","first-page":"633","DOI":"10.3233\/JAD-132735","volume":"41","author":"Gareri P.","year":"2014","unstructured":"Gareri P.; Putignano D.; Castagna A.; Retrospective study on the benefits of combined Memantine and cholinEsterase inhibitor treatMent in AGEd Patients affected with Alzheimer\u2019s Disease: the MEMAGE study. J Alzheimers Dis 2014,41(2),633-640","journal-title":"J Alzheimers Dis"},{"key":"ref=134","doi-asserted-by":"publisher","first-page":"9708","DOI":"10.1021\/jm3009458","volume":"55","author":"Simoni E.","year":"2012","unstructured":"Simoni E.; Daniele S.; Bottegoni G.; Combining galantamine and memantine in multitargeted, new chemical entities potentially useful in Alzheimer\u2019s disease. J Med Chem 2012,55(22),9708-9721","journal-title":"J Med Chem"},{"key":"ref=135","doi-asserted-by":"publisher","first-page":"123","DOI":"10.2174\/1871524916666160625123621","volume":"17","author":"Fornasari E.","year":"2017","unstructured":"Fornasari E.; Marinelli L.; Di Stefano A.; Synthesis and antioxidant properties of novel memantine derivatives. Cent Nerv Syst Agents Med Chem 2017,17(2),123-128","journal-title":"Cent Nerv Syst Agents Med Chem"},{"key":"ref=136","doi-asserted-by":"publisher","first-page":"4612","DOI":"10.1038\/s41598-019-40925-8","volume":"9","author":"Sestito S.","year":"2019","unstructured":"Sestito S.; Daniele S.; Pietrobono D.; Memantine prodrug as a new agent for Alzheimer\u2019s Disease. Sci Rep 2019,9(1),4612","journal-title":"Sci Rep"}],"container-title":["Current Pharmaceutical Design"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/eurekaselect.com\/article\/download\/175567","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,12,17]],"date-time":"2019-12-17T10:24:11Z","timestamp":1576578251000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.eurekaselect.com\/175567\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11,19]]},"references-count":136,"journal-issue":{"issue":"33","published-print":{"date-parts":[[2019,11,19]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1381612825666191011102444","relation":{},"ISSN":["1381-6128"],"issn-type":[{"value":"1381-6128","type":"print"}],"subject":[],"published":{"date-parts":[[2019,11,19]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2019-09-23","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-10-08","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-11-19","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}